ERBB2 and breast carcinoma: For HER2 + breast cancer, Courtney A. Bartel, and Mark W. Jackson found that decreased FAM83A expression can inhibit HER2 + breast cancer cell proliferation, promote cell apoptosis, and inhibit the PI3K pathway; however, this was not related to trastuzumab sensitivity [31].